DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Daniel Tassé will engage in a fireside chat on September 9, 2025, at 11:30am ET in New York.
The presentation will be accessible through a live webcast and will remain available for replay on the company's investor relations website for 90 days after the event.
DBV Technologies (NASDAQ:DBVT), azienda biofarmaceutica in fase clinica, ha comunicato la sua partecipazione al 27° H.C. Wainwright Annual Global Investment Conference. Il CEO Daniel Tassé parteciperà a un fireside chat il 9 settembre 2025 alle 11:30 ET a New York.
La presentazione sarà trasmessa in diretta via webcast e resterà disponibile in replica sul sito investor relations della società per 90 giorni dopo l'evento.
DBV Technologies (NASDAQ:DBVT), una compañía biofarmacéutica en fase clínica, anunció su participación en la 27ª Conferencia Anual Global de Inversión de H.C. Wainwright. El CEO Daniel Tassé participará en un fireside chat el 9 de septiembre de 2025 a las 11:30 ET en Nueva York.
La presentación se podrá ver mediante una transmisión en vivo (webcast) y permanecerá disponible en reproducción en el sitio de relaciones con inversores de la compañía durante 90 días tras el evento.
DBV Technologies (NASDAQ:DBVT), 임상 단계의 바이오제약 기업이 H.C. Wainwright 27회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CEO 다니엘 타세(Daniel Tassé)가 2025년 9월 9일 동부시간(ET) 오전 11시 30분에 뉴욕에서 파이어사이드 토크(fireside chat)에 참석합니다.
발표는 라이브 웹캐스트로 시청할 수 있으며, 행사 종료 후 90일간 회사의 투자자 관계 웹사이트에서 다시보기로 제공됩니다.
DBV Technologies (NASDAQ:DBVT), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 27e conférence annuelle mondiale d'investissement H.C. Wainwright. Le CEO Daniel Tassé participera à un fireside chat le 9 septembre 2025 à 11h30 ET à New York.
La présentation sera diffusée en direct via webcast et restera disponible en replay sur le site des relations investisseurs de la société pendant 90 jours après l'événement.
DBV Technologies (NASDAQ:DBVT), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 27. H.C. Wainwright Annual Global Investment Conference angekündigt. CEO Daniel Tassé wird am 9. September 2025 um 11:30 Uhr ET in New York an einem Fireside-Chat teilnehmen.
Die Präsentation wird per Live-Webcast zugänglich sein und steht für 90 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens als Wiederholung zur Verfügung.
- None.
- None.
Châtillon, France, September 3, 2025
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:30am ET, in New York, NY.
A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
When is DBV Technologies (DBVT) presenting at the H.C. Wainwright Conference?
How can investors access DBV Technologies' H.C. Wainwright Conference presentation?
How long will DBV Technologies' conference presentation be available for replay?
Who will be presenting for DBV Technologies at the H.C. Wainwright Conference?
